This article was originally published in Start Up
For the ultimate in convenience, hundreds of thousands of nearsighted and farsighted patients are turning to refractive surgery, or surgical vision correction procedures that promise a permanent alternative to glasses. New companies that wish to grab a portion of the $12 billion US market for vision correction are avoiding the crowded and competitive excimer laser business, with technologies that treat patients that LASIK (laser in-situ keratomileusis) doesn't serve well.
You may also be interested in...
NeuroVision Inc. is looking behind the eye to correct vision problems. It is targeting the back of the brain with a Web-based, noninvasive, patient-specific treatment designed to re-wire the neural connections responsible for vision. The company will first target adult amblyopia, and then move on to presbyopia, myopia and other visual disorders.
Phakic intraocular lenses may offer solutions for patients that suffer from high degrees of myopia or hyperopia, Medennium Inc. 's PRL, in phase II clinical trials, is a posterior phakic intraocular lens.
Refractec hopes to offer a low-cost alternative to LASIK, a new, non-laser treatment for the underserved group of patients that suffers from farsightedness or hyperopia.